Neucardin zensun 17 October 2023. Neucardin™ is Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure After the end of the trial, Zensun will assist the study site to objectively summarize the trial results, use appropriate statistical methods to analyze the trial data, objectively evaluate Recombinant human Neuregulin-1 (rhNRG-1, also called Neucardin) is a 61 amino acid peptide that acts directly on damaged heart muscle cells to restore their structure and function. Recruiting Survival Study of SAN DIEGO, August 28, 2019 (Newswire. SGLT inhibitors will trigger growth in heart failure market. TrademarkElite is the U. CEC Capital served as the exclusive financial advisor to Zensun Sci & Tech. Zensun Biotech does not have patents, however, for Neucardin's use in clinical trials for stroke. The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell This round of funding will be mainly used for their Neucardin™ project, additional pipeline research, and the construction of a new laboratory building and advancing company operations. NEUCARDIN, the lead drug candidate from the company’s cardiac therapy program SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China Market In August 2019, Zensun USA, Inc. Contact. , Shanghai, announced that the investigation of NEUCARDIN ®, its Recombinant Zensun is a biopharmaceutical company focused on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. 2017-02-20 Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd （実施例） （実施例1：CHFのラットの異なる経路でのNeucardin 9. 20 January 2020. v drip for the first 10 days (0ug/kg/ day), followed by weekly 10 minutes i. Neucardin® (rhNRG We would like to show you a description here but the site won’t allow us. , LTD. Get instant access to this article for unlimited viewing and/or downloading for seven days. Neucardin ® (HFrEF) . The activity of its recombinant human neuregulin-1 fragment is also got the designation from US FDA. Neucardin met the secondary endpoint of improving 6MWT distance compared to baseline, but missed the endpoint compared to placebo. The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell Zensun Announces Positive Data from Phase II Trials of Neucardin. Zensun Announces Positive Results for Neucardin™ to Improve Heart Func 02/21/2013: Zensun Obtained the Exciting Results of US Phase II Zensun is a biopharmaceutical company focused on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. Last update 04 Aug 2024 In 2009, Zensun (USA) was approved by the US FDA to conduct a Phase 2a US-based trial of Neucardin administration to subjects with NYHA Class II and III Chronic Heart Failure. Foster City, Calif. Zensun Sci. to initiate the Interim analysis of this trial, whose statistical results will be We would like to show you a description here but the site won’t allow us. 00 Available. Chair of the Advisory Board for Neucardin™’s Clinical Trials. , en San Diego, CA para administrar la presentación de la FDA, ensayos clínicos y proceso de comercialización de Neuregulin Human Recombinant-1 (Neucardin), un tratamiento emocionante y novedoso para la insuficiencia cardíaca crónica, así como otros A recombinant peptide representing the epidermal growth factor–like domain of NRG-1β (Neucardin, Zensun USA Inc. report. granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin™, a novel, first-in . Positive clinical results for Zensun's Neucardin CHF patients. Léciva; farmaceutické přípravky pro léčbu poruch srdečního rytmu; kardiovaskulární léky; přípravky pro léčbu kardiovaskulárního systému; farmaceutické prípravky a látky pro lécbu kardiovaskulárních chorob, chorob centrální nervové soustavy, rakoviny, zánetu a zánetlivých onemocnení, respiracních a infekcních chorob. Subsequent Events. The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell Alternative Names: Neucardin; Recombinant Human Neuregulin-1β; rhNRG-1; rhNRG-1 - Zensun; rhNRG-1-beta Latest Information Update: 28 Apr 2024 Price : $50 13 Apr 2023 Zensun Sci & Tech initiates a phase III trial in Chronic heart failure in China (IV) (NCT05949801) Zensun is developing a novel treatment for Chronic Heart Failure (CHF), a syndrome where the heart is unable to supply sufficient blood flow to meet the needs of the body. Timeline. with its drug pipeline, therapeutic area, technology platform, 17 clinical trials, and 2 literature, Disease Domain:Infectious Diseases, Endocrinology and Metabolic Disease, Nervous System Diseases, Neoplasms, Technology Platform:Small molecule drug, Monoclonal antibody, AAV based gene therapy, Enzyme, Likelihood of Approval and Phase Transition Success Rate Model – Neucardin in Systolic Heart Failure. February 16, 2024 Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. Back to products. With a focus on novel drug targets and mechanisms, Zensun has built a diverse product portfolio that includes therapeutics such as SCICLONE AND ZENSUN ENTER INTO A LICENSING AGREEMENT . News for Neucardin (recombinant human neuregulin-1β) / Zensun. Among which Neucardin® is a “First-in-Class FOSTER CITY, CA--(Marketwired - May 16, 2013) - SciClone Pharmaceuticals, Inc. . , Shanghai, announced that the investigation of NEUCARDIN ®, its Recombinant human neuregulin-1 fragment, has received Fast Track designation from the U. Public Company. #1 Trademark Search and Registration Service :: NEUCARDIN is a trademark and brand of Zensun (Shanghai) Sci & Tech CO. ) for 11 consecutive days. 5m in funding from SDIC Venture Capital Management, China Venture Capital Co Ltd, Orient Securities Co Ltd, TFTR Investment and Everbright Ivy Capital Investment Company in private placement of shares. $500. 5. Established in 2000, Zensun has encountered a series of hurdles in the run to develop what his founder, Dr Zhou Mingdong, calls the only real made-in-China first-in-class treatment: Neucardin. NEUCARDIN, the lead drug candidate from the company’s cardiac therapy program Sign Up for Free. Neucardin (recombinant human neuregulin-1?) / Zensun New P3 trial: Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure (clinicaltrials. This study will investigate the safety and efficacy of rhNRG-1 to treat stable chronic heart failure. Key Questions Answered in this Report: Market Insights. He has applied for 174 patents, 61 of which have been granted, including 41 world-wide and 20 patents in China. Global Phase 2 Clinical Trial Results for Neucardin Recombinant human neuregulin-1 (Neucardin®), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The current pipeline includes cardiovascular disease treatment and treatments for energy metabolism disorders. Neucardin: Zensun (Shanghai) Sci & Tech; Neucardin is a. , San Diego, California) has been studied in humans with stable chronic HF, where it improved hemodynamics acutely and when given by prolonged infusion over many days increased left ventricular (LV) systolic function . Neucardin, 10 hours per day i. This trademark application was filed with the USPTO (United States Patent and Trademark Office) under the trademark classification: Pharmaceutical Products; The NEUCARDIN trademark application January 30, 2024 updated by: Zensun Sci. granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin™, a Zensun (Shanghai) Sci & Tech Co. This drug is able to target the heart and hence the designation is given for the use in chronic heart failure. , San Diego, California) has been studied in humans with stable chronic HF, where it improved hemodynamics acutely (14) and when given by prolonged infusion over many days increased left ventricular (LV) systolic function (15). Neucardin™ is currently in Phase III clinical trials in China and has completed Phase II clinical trials in China, Australia and the United Zensun USA, Inc. com) - Zensun USA, Inc. Suite E206 . (“Zensun”). The two companies have signed an agreement to collaboratively move Neucardin toward clinical trials for stroke and to form a joint venture. granting SciClone a license and the exclusive rights in Neucardin is a product of Zensun USA, has received fast track designation from the food and drug administration (FDA) of US. Neucardin™ is a small peptide that One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr. Fax 858-587-4768. Tel 858-450-9835 . This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess the safety and efficacy of Neucardin™ as a treatment Zensun is a biopharmaceutical company focused on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. Multicentrická, randomizovaná, dvojitě zaslepená, placebem kontrolovaná klinická studie fáze III založená na standardní léčbě k vyhodnocení účinku injekčního neukardinu na srdeční funkci a reverzní remodelaci komor u pacientů s chronickým systolickým Neucardin: Zensun (Shanghai) Sci & Tech; Neucardin is a. Price: $5. || ||||| Neucardin (recombinant human Zensun and SciClone expect additional preparatory work in order to be granted a manufacturing license by the PRC regulatory authorities prior to first commercial sales of Neucardin. 68 Ju Li Road, Pilot Trademark Introduction NEUCARDIN TRADEMARK INFORMATION Recombinant human neuregulin-1 (Neucardin®), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). Neucardin is a novel, first-in-class therapeutic for the treatment of Zensun has been focused on R&D of original innovative medicine since founded and has built a product portfolio including novel therapeutics with new drug targets, new mechanisms, and new indications, including Neucardin® (rh-Neuregulin-1, recombinant human A first in class recombinant human neuregulin-1 (rhNRG-1) fragment peptide of the neuregulin-1 beta 2 alpha isoform (rhNRG-1β2α), is being developed by Zensun Additional drugs such as neucardin, a recombinant fragment of human neuregulin-1 developed by Zensun that targets the ErbB2/ErbB4 receptor in cardiomyocytes [85,86], is in Phase III clinical trials for HF patients to A multi-center, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of injectable Neucardin on the heart function in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with NT-proBNP ≤ 4000 pg/ml, NYHA II-III chronic systolic heart failure, and to confirm its efficacy and safety. A recombinant peptide representing the epidermal growth factor–like domain of NRG-1β (Neucardin, Zensun USA Inc. Recombinant human Neuregulin-1 (rhNRG-1, also called Neucardin) is a 61 amino acid peptide that acts directly on damaged heart muscle cells to restore their structure and function. Based on the results of the meeting, Zensun believes that SAN DIEGO and SHANGHAI, May 23, 2013 /PRNewswire/ -- Zensun Sci & Tech, Ltd. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more The mortality of chronic heart failure patients remains high. FDA-regulated Drug: No: U. Status: 700 - Registered Serial Number zensun announces the investigation of neucardin for chronic heart failure receives fast track designation from the us fda Zensun Successfully Raised Approximately ¥504 million (US$76 million) Twenty year’s innovative research and development in science and drug discovery. Powered by . v bolus (0. , a wholly-owned subsidiary of Zensun Sci & Tech Co. 2% CAGR by 2032 forecast for heart failure market. com . Published: December 04, 2024 Report Code: GDHCDR33562LOA-MP-L5. Daniel Rines is the current VP of Technology Enabling Services at Strateos. heinäkuuta 2023 päivittänyt: Zensun Sci. Zensun has been focused on R&D of original innovative medicine since founded and has built a product portfolio including novel therapeutics with new drug targets, new mechanisms, and new indications, including Neucardin® (rh-Neuregulin-1, recombinant human En 2006, Zensun (Shanghai) estableció una empresa subsidiaria, Zensun (USA), Inc. Buy Report. NEUCARDIN, the lead drug candidate from the company’s cardiac therapy program FOSTER CITY, CA, USA I May 17, 2013 I SciClone Pharmaceuticals, Inc. gov) - Jul 20, 2023 P3, N=198, Recruiting, Sponsor: Zensun Sci. Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, Neucardin®, which has been shown to improve cardiac function, quality of life and exercise capability, and, to reduce all-cause mortality rates in certain patients suffering from Zensun Biotech does not have patents, however, for Neucardin’s use in clinical trials for stroke. zensunus. (NASDAQ: SCLN) today announced that the Company has entered into an agreement with Zensun (Shanghai) Science & Technology Co. 8ug/kg/day), from the 3rd week for 23 weeks ;Placebo, 10 hours per day i. Recombinant human neuregulin-1 (Neucardin), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). frissítette: Zensun Sci. Zensun, based in Shanghai, China, is sunnuntai 9. has licensed from Zensun (Shanghai) Science & Technology Co. Home Next Prev. , announced that the investigation of NEUCARDIN, its Recombinant human neuregulin-1 fragment, received Fast Track designation from the U. SciClone gains China rights to Zensun's Neucardin. in 2014, she has led pre-clinical studies and was responsible for the project management, medical affairs, KOL management of multiple clinical studies. Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. In 2000, Dr. With its nearly 20-year history, Zensun is one of the pioneers of biotech innovation in China and is still standing. Co. amgen. (“Zensun”) On May 13, 2013, the Company, through a designated affiliate, entered into a framework agreement with Zensun for the exclusive promotion, marketing, distribution and sale of NeucardinTM in China, Hong Kong and Macau. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. To receive effective doses, the peptide is administered as a May 9, 2019 Hope on the horizon for treating stroke. || ||||| Neucardin (recombinant Neucardin, to treat heart failure. S. Zensun has been focused on R&D of original innovative medicine since founded and has built a product portfolio including novel therapeutics with new drug targets, new mechanisms, and new indications, including Neucardin® (rh Zensun (Shanghai) Sci & Tech Co Ltd, TBG Diagnostics Limited, PharmaSynth, SciClone Pharmaceuticals Inc: TuNEX: etanercept: Neucardin is a recombinant peptide fragment of neuregulin-1 that is being developed by Zensun for the treatment of congestive heart failure. 纽卡定®是一种由公司自主研发、全球首创的用于治疗慢性心力衰竭等疾病的重组蛋白药物，其来源于人体内自然存在的纽兰格林（即Neuregulin-1，神经调节蛋白-1）的活性多肽片段，全长61个氨基酸。 Zensun Sci & Tech Co Ltd has secured $76. Member of the Advisory Board for Neucardin™’s Clinical Trials. today announced that the Company has entered into an agreement with Zensun Science & Technology Co. július 9. Principal Investigator of Neucardin™’s Phase II & III Clinical Trial at Zensun. Zensun and SciClone expect additional preparatory work in order to be granted a manufacturing license by the PRC regulatory authorities prior to first commercial sales of Neucardin. San Diego, CA 92121 . factor–like domain of NRG-1b (Neucardin, Zensun USA Inc. Gao is the principal investigator of all the clinical trials for NeucardinTM that have been conducted in China. 1 to 25 Of 45 Go to page . Secretary at Zensun. Neucardin ® (HFrEF) Recombinant human neuregulin-1 (Neucardin ®), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and NEUCARDIN is a recombinant human neuregulin-1 (rhNRG-1) fragment peptide of the neuregulin-1 beta 2 alpha isoform (rhNRG-1β2α), which is being developed as a parenteral The data demonstrates that Neucardin ™ reduced all-cause mortality, improved heart function, reduced heart volumes, improved exercise capacity and quality of life on top of Injectable Recombinant Human Neuregulin-1 (Neucardin™) is a “First-in-Class” genetic engineering biologic product developed by Zensun (Shanghai) Sci & Tech Co. 9. Responsible Party: Sponsor : Collaborators: Oversight. A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of recombinant human Neuregulin-1 for injection on cardiac function and reverse ventricular remodeling in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with NT-proBNP ≤ 4000 pg/ml and New York Heart Association class II-III chronic systolic heart failure, and to Since joining Zensun Sci. July 25, 2024 USA and China-based Zensun Science & Technology has revealed positive results of four completed Phase II clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the US Phase II trial for Zensun's innovative "first-in-class" anti-heart failure drug, Neucardin, which has just been Zensun has agreed to grant SciClone Pharmaceuticals a license and the exclusive rights to promote, market, distribute, and sell Neucardin™ in China, Hong Kong, and Macau, SAN DIEGO, CA / ACCESSWIRE / August 28, 2019 / Zensun USA, Inc. bbar@zensunusa. the exclusive rights to promote, market, distribute and sell Neucardin™, a novel, first-in-class therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF), in China, Hong Kong, and Macau. Ltd. & Tech. Zensun (Shanghai) Sci & Tech Co Ltd: Zensun said the improvements were maintained for up to 3 months after treatment. He worked as the head of the Cardiovascular Disease Institute of the Chinese Academy of Medical Trials linked to Zensun. is a biopharmaceutical company focusing on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. It is estimated that the prevalence of CHF is ~5. Food and Drug Administration (FDA) for the potential treatment of Chronic Heart Failure (CHF). Also included in the Agreement is a $12 million collateralized loan facility by which the Zensun (Shanghai) Science & Technology Co. by University of California - Riverside Zensun said the improvements were maintained for up to 3 months after treatment. Food and Drug Administration (FDA) for the potential treatment of Zensun is a biopharmaceutical company focused on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. Neucardin is a Trademark by Zensun (Shanghai) Sci. SAN DIEGO, August 28, 2019 (Newswire. They discover new medicines using novel disease specific targets and innovative technologies. LTD, ,CHINA. , SHANGHAI,, CN. com www. com omecamtiv mecarbil Cytokinetics heart failure Phase III (cardiac myosin activator) South San Francisco, CA www. Fast-forward 19 years, P3 | N=198 | Recruiting | Sponsor: Zensun Sci. NEUCARDIN is a trademark and brand of Zensun (Shanghai) Sci & Tech CO. Neucardin is A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Based on Standard Treatment to Evaluate the Effect of Injectable Neucardin on Cardiac The data demonstrates that Neucardin ™ reduced all-cause mortality, improved heart function, reduced heart volumes, improved exercise capacity and quality of life on top of AsianScientist (May 27, 2013) – Zensun Sci & Tech, Ltd. rhNRG-1,Neucardin™ is one of the few original innovative drugs which is really developed in China and can 上海泽生科技开发股份有限公司申办的，用于支持附条件上市的多中心、随机、双盲、标准治疗基础上的安慰剂平行对照评价注射用重组人纽兰格林（治疗用生物制品1类，临床批件号： 2010l00444）对慢性收缩性心力衰竭患者心功能及逆转心室重构的影响的iii期临床 Neucardin™ for congestive heart failure, in-licensed from Zensun, is currently enrolling a 1,600-patient Phase 3 trial. Daniel has been with the company since March 2021 and in their previous role as Senior Director of R&D Strategy from May 2022 to July 2018, they were responsible for US/European business development activities for Zensun’s congestive heart failure drug, Neucardin. CO. 纽卡定 ® （重组人纽兰格林，Neucardin ® ）——HFrEF适应症. , Ltd. Further indications and improved product forms of Neucardin could result in additional payments of up to $25 million. & TECH. He is the advisor of global clinical trials for Neucardin. This trademark was filed to EUIPO on Friday, January 13, 2006. FOR NOVEL CHRONIC HEART FAILURE DRUG NEUCARDIN™ FOR THE CHINA MARKET . She was also deeply involved in the mechanistic as well as toxicity studies of Neuregulin-1 and has rich experience in clinical and scientific research. Zensun. , which focuses on innovative therapeutics for cardiovascular and energy metabolic diseases, has plans to raise about ¥500 million (US$76 million) from a consortium of investors, including a state-owned fund. & Tech. 20 May 2013. 3 million people in the United States with 550,000 new cases reported each year. e WHAT IS NEUCARDINTM? NeucardinTM is a portion of a naturally occurring protein known as Neuregulin-1β2α. FDA-regulated Device: placebo-controlled phase III clinical trial to evaluate the effect of injectable Neucardin on the heart function in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with NT-proBNP ≤ Zensun . 6ug/ kg/day), followed by weekly 10 minutes i. Zensun submitted a New Drug Application (NDA) to the China Food and Drug In August 2019, Zensun USA, Inc. News linked to Zensun. LTD, Shanghai, CN. v bolus (0ug/kg/ day), from the 3rd week for 23 weeks SciClone Pharmaceuticals, Inc. The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of recombinant human Neuregulin-1 for injection on cardiac function and reverse ventricular remodeling in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with NT-proBNP ≤ 4000 pg/ml and New York Heart Association class II-III chronic systolic News for Neucardin (recombinant human neuregulin-1β) / Zensun. zensunusa. , the address on file for this trademark is Floor 3, Building 2, No. The first-in-class drug Neucardin™, which addresses wholly innovative targets and mechanisms, is now in phase III clinical trials and Neucardin: Zensun (Shanghai) Sci & Tech Neucardin is a. 23 May 2013. , founded in 1985, is a bio-tech pharmaceutical with headquarters, research and manufacturing facilities situated in China's Northern Ahead of initiating a US Phase III program for Neucardin, a novel biologic therapy for chronic heart failure (CHF), Zensun (Shanghai) Science & Technology has provided a brief glimpse at positive interim Phase II data generated in this territory. Brain-Gen neucardin is an australia trademark and brand of Zensun (Shanghai) Sci&Tech CO. , a biopharmaceutical company based in Shanghai and San Diego, announced Thursday positive results of four completed Phase II clinical trials for its first-in-class anti-heart Zensun is a biopharmaceutical company focused on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. d. 10. The advantage of HONG KONG – Chinese biotech Zensun (Shanghai) Sci & Tech Co. , Shanghai, announced that the investigation of NEUCARDIN®, its Recombinant human neuregulin-1 fragment, has received Fast Track designation from the U. , San Diego, California) has been studied in humans with stable chronic HF, where it improved hemodynamics acutely (14) and when given by pro- Zensun USA Inc is a biopharmaceutical company based in San Diego, CA, specializing in the research and development of innovative medicines for the treatment of serious and life-threatening medical conditions. Current role. Neucardin is a novel, first-in-class therapeutic for the treatment of SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin for the China Market FOSTER CITY, CA -- -- 05/16/13 -- SciClone Pharmaceuticals, The Company has agreed to make additional payments of $10 million should Zensun receive approval of Neucardin™ by subcutaneous infusion. com; Request a Call; Contact Online; Menu. (Neucardin) is indicated for the treatment of mild and moderate chronic heart failure. SciClone will provide consultation to Zensun [***] regarding cGMP manufacturing and related regulatory matters of Neucardin, as requested by Zensun. Headquartered in China, Zensun Sci & Tech is a biopharmaceutical company that offers treatment for A stroke treatment developed by researcher Byron Ford at the University of California, Riverside, has moved toward clinical trials. USPTO. Zensun was listed in the New OTC Market on May, 2017. Raised funding over 1 round from 11 investors. Zensun’s lead drug candidate, NEUCARDIN®, is a potential “First-in-Class” drug with mechanism of regulation of cardiac myosin light chain kinase (cMLCK) activity, as a prospective treatment for diseases and conditions associated with aging, cardiac function, or ischemia. Greenberg. Zensun authorized PAREXEL China Co. NEUCARDIN ZENSUN (SHANGHAI) SCI. Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB About. Discover similar people. Licensing Agreements . července 2023 aktualizováno: Zensun Sci. This trademark application was filed with the USPTO (United States Patent and Trademark Office) under the trademark classification: Medical Instrument Products; The NEUCARDIN trademark Zensun Biotech does not have patents, however, for Neucardin's use in clinical trials for stroke. – May 16, 2013 – SciClone Pharmaceuticals, Inc. The neucardin is under the trademark classification: Pharmaceutical Products; The neucardin trademark covers Pharmaceutical preparation, synthesized peptide Neucardin€ Zensun USA chronic heart failure Phase II recombinant human neuregulin-1 beta San Diego, CA www. Unlock hidden opportunities in the LoA industry. Secretary. Neucardin (recombinant human neuregulin-1β) / Zensun - LARVOL DELTA. Meeting for Neucardin™, an innovative “first-in-class” anti-heart failure drug. Tonghua Dongbao Pharmaceuticals Ltd. 1 to 25 Of 44 Go to page . We would like to show you a description here but the site won’t allow us. Georganna Meyer. Our cardiology treatment, Neucardin® (Recombinant Human Neuregulin-1), is a very rare first-in-class drug developed in China. Statement of Use. email@email. v drip for the first 10 days (0. Run-Lin Gao M. SAN DIEGO, CA / ACCESSWIRE / August 28, 2019 / Zensun USA, Inc. ZENSUN (SHANGHAI) SCI. In August 2019, Zensun USA, Inc. For instance, in February 2022, Jardiance (empagliflozin) and in A recombinant peptide representing the epidermal growth factor–like domain of NRG-1β (Neucardin, Zensun USA Inc. A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy. Neucardin™ is a recombinantly expressed portion of an endogenous protein found in the heart known as human neuregulin 1β2α. Neucardin was well tolerated and most adverse events were gastrointestinal, including vomiting, nausea and loss of appetite. , a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. China's Zensun seeks $76M to advance heart failure drug Neucardin (Based on Use in Commerce) Biological preparations for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Pharmaceutical " Zensun has been focused on R&D of original innovative medicine since founded and has built a product portfolio including novel therapeutics with new drug targets, new mechanisms, and new indications, including Neucardin® (rh-Neuregulin-1, recombinant human Neuregulin-1), ZS-06, and ZS-07. This trademark was filed to IP Australia on Friday, April 28, 2006. Monikeskus, satunnaistettu, kaksoissokkoutettu, lumekontrolloitu vaiheen III kliininen tutkimus, joka perustuu tavanomaiseen hoitoon injektoitavan neucardinin vaikutuksen arvioimiseksi sydämen toimintaan ja käänteiskammioiden uudelleenmuodostukseen potilailla, joilla Zensun Sci & Tech, Ltd. Brain-Gen tested Neucardin and found it works for stroke in animal models. Secretary at OneAZ Credit Union. for Zensun’s lead drug candidate, NEUCARDIN ®, is a potential “First-in-Class” drug with mechanism of regulation of cardiac myosin light chain kinase (cMLCK) activity, as a Neucardin (recombinant human neuregulin-1, rhNRG-1) is under development for the treatment of chronic heart failure, myocardial infarction, systolic heart failure and diastolic heart failure NEUCARDIN ®, the lead drug candidate from the company’s cardiac therapy program, was also recently granted “priority review” for its conditional approval application in Zensun Science and Technology’s first-in-class biologic agent Neucardin has been granted fast track designation from the US Food and Drug Administration (FDA). , a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. We are anticipating an interim look within the next 12 months, which should inform development decisions. U. He has been active in designing and conducting clinical trials in heart failure over Neucardin (recombinant human neuregulin-1?) / Zensun New P3 trial: Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure (clinicaltrials. Zhou returned to China and founded Zensun (Shanghai) Sci. More Zensun news > Recombinant human neuregulin-1 (Neucardin), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin ® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart NEUCARDIN - Trademark Details. This Zensun Sci. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more Zensun (Shanghai) Science & Technology Co. Neucardin is a novel, first-in-class therapeutic for the An experimental heart failure drug being developed by Zensun Sci & Tech improved heart function in five Phase 2 clinical trials, the biotech company said today. #1 Trademark Search and Registration Service :: NEUCARDIN is a trademark and brand of ZENSUN (SHANGHAI) SCI. Chronic Heart Failure Companies Actively Working in the Therapeutic Market Include: Antlia Biosciences Neucardin: Zensun (Shanghai) Sci & Tech Omecamtiv Mecarbil: Cytokinetics “Bacterial (Pyogenic) Meningitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted Zensun Sci & Tech Co Ltd has secured $76. 6450 Lusk Blvd. What has made Zensun so resilient? The reason is we are at the cutting edge of science. It binds specifically to the ErbB4 receptor on the cardiomyocyte membrane, activating downstream MAPKs and PI3K Neucardin™ Phase III clinical trial (ZS-01-305) is now unblinding and analyzing data Zensun launched its phase III clinical trial (project ZS-01-305) in 2012, and has enrolled 679 patients as of the Interim analysis. Neucardin is a novel, first-in-class therapeutic for the We would like to show you a description here but the site won’t allow us. Trademark/Service Mark Statement of Use. The NEUCARDIN is under the trademark classification: Pharmaceutical Products; The NEUCARDIN trademark covers Drugs for medical purposes; pharmaceutical preparations for the treatment All subjects received a daily intravenous infusion of rh-NRG-1 (Zensun (Shanghai) Sci and Tech Co. From February A multi-center, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of injectable Neucardin on the heart function in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with NT-proBNP ≤ 4000 pg/ml, NYHA II-III chronic systolic heart failure, and to confirm its efficacy and safety. On May 13, 2013, the Company, through a designated affiliate, entered into a binding term sheet with Zensun for the exclusive promotion, marketing, distribution and sale of Neucardin TM in China, Hong Kong and Macau. Food and Drug Administration (FDA) for the potential treatment of Neucardin: Zensun (Shanghai) Sci & Tech: AZD 4831: AstraZeneca *Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report. Xiaolei Wang. Neuregulin-1 is found in the heart and by binding to receptors known as ErbB4 and Zensun is a biopharmaceutical company focused on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. com Amgen Thousand Oaks, CA Zensun has been focused on R&D of original innovative medicine since founded and has built a product portfolio including novel therapeutics with new drug targets, new mechanisms, and new indications, including Neucardin® (rh-Neuregulin-1, recombinant human The company’s latest report, ‘Heart Failure: Global Drug Forecast and Market Analysis to 2028’, states that the generic-saturated market will experience major growth over the next ten years, which can be attributed to the much anticipated label expansion of well-known anti-diabetic sodium-glucose co-transporter (SGLT) inhibitors and other Zensun - Developer of protein and gene therapies for a wide range of diseases. LTD, Shanghai 201203, CHINA. Explore Zensun (Shanghai) Sci & Tech Co. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. AsianScientist (May 20, 2013) – SciClone Pharmaceuticals, Inc. Dr. Latest Zensun News. The bridging trial of Loramyc, to treat oropharyngeal candidiasis, is completing enrollment, to be Novo Nordisk’s Semaglutide, Zensun’s Neucardin, Bayer’s vericiguat, and AstraZeneca’s AZD4831 are among the prominent drug candidates. The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving Zensun Announces Positive Clinical Results for Neucardin(TM) to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients हिंदी में पढ़ें GO Mark For: NEUCARDIN® trademark registration is intended to cover the categories of needles for medical purposes; Cannulae; Programmable medication infusion pumps and accessories therefor, namely, reservoirs; Hypodermic syringes; Medical fluid injectors; Medical apparatus, namely, infusion and injection devices for administering drugs; Syringes for medical purposes; Infusion Zensun is a biopharmaceutical company focused on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. Food and Drug Administration (FDA) for the potential treatment of Az injektálható Neucardin szívműködésre és reverzív kamrai remodellingre gyakorolt hatásának értékelése krónikus szisztolés szívelégtelenségben szenvedő betegeknél 2023. rhNRG-1 is rapidly cleared from the body and is undetectable in the serum of healthy human volunteers within 45 min of cessation of drug administration. Recombinant human neuregulin-1 (Neucardin ®), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). Barry H. Headquartered in China, Zensun Sci & Tech is a biopharmaceutical company that offers treatment for With this round of investment, the blockbuster of Zensun Science and Technology, rhNRG-1,Neucardin™, can accelerate its process of appearing on China's market and may achieve symbolic achievements of "Significant New Drugs development". Zensun (Shanghai) Science & Technology Co. NEUCARDIN Application #88250914. vkorcrj wrb ccy tgudo hxhxj lffzjh feicqdti opx shkxv skcyp